CompletedPhase 2NCT00332956

Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers

Studying Plague

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: DynPort Vaccine Company LLC, A GDIT Company
Principal Investigator: Ivor Emmanual, MD
Benchmark Research
Intervention: rFIV vaccine(biological)
Enrollment: 400 target
Eligibility: 18-55 years · All sexes
Timeline: 2006 – 2008

Study locations (9)

Alta Clinical Research, LLC, Tucson, Arizona, United States
Benchmark Research, San Francisco, California, United States
Palm Beach Research, West Palm Beach, Florida, United States
University of Kentucky - Dept. of Infectious Disease, Lexington, Kentucky, United States
Sundance Clinical Research, St Louis, Missouri, United States
Infectious Disease Specialists, PC, Missoula, Montana, United States
Meridian clinical Research, LLC, Omaha, Nebraska, United States
Clinical Research Center of Nevada, Las Vegas, Nevada, United States
Primary Physicians Research, Inc., Pittsburgh, Pennsylvania, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00332956 on ClinicalTrials.gov

Other trials for Plague

Additional recruiting or active studies for the same condition.

See all trials for Plague →

← Back to all trials